10-15 Nov 21 – LSX Inv€$tival Showcase conference.

Small Pharma is participating in the LSX Inv€$tival ShowcaseTM conference.

Peter Rands, Chief Executive Officer, and Dr. Carol Routledge, Chief Medical and Scientific Officer, are presenting a webcast on the Company’s progress in the development of N,N-dimethyltryptamine (“DMT”) assisted therapy for the treatment of Major Depressive Disorder (“MDD”), which is available on-demand via the conference platform.

Small Pharma’s management team is also available for one-on-one in-person meetings on November 15 in London, England. To schedule a meeting, please contact LifeSci Advisors at

About Small Pharma

We’re a mental health drug development company that’s accelerating the development of fast acting antidepressant treatments using DMT based therapies. We’re dedicated to making a difference.

With a focus on innovative approaches and committed to challenging the status quo, we’re targeting the root causes of depression and hoping to unlock the minds of millions.

Get Small Pharma updates

    Investor Deck

    Follow us: